비교리스트

 카트 문의
시장보고서
상품코드
1625376

리포좀 독소루비신 시장 규모, 점유율, 동향, 산업 분석 보고서 : 제제별, 제품별, 유형별, 투여 경로별, 용도별, 최종사용자별, 지역별 - 시장 예측(2025-2034년)

Liposomal Doxorubicin Market Size, Share, Trends, Industry Analysis Report: By Drug Formulation, Product, Type, Route of Administration, Application, End User, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 리포좀 독소루비신 세계 시장 규모는 2034년까지 23억 8,000만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

리포좀 독소루비신 시장은 암 발병률 증가와 효과적인 표적 치료제에 대한 수요 증가로 인해 큰 성장세를 보이고 있습니다. 기존 독소루비신에 비해 부작용이 적고 치료 효과를 높이는 전달 메커니즘의 개선도 시장 성장의 원동력이 되고 있습니다.

적응증 확대와 제형 기술 개선에 중점을 둔 연구개발이 진행되고 있으며, 이는 예측 기간 동안 시장에 유리한 기회를 제공할 것으로 예상됩니다. 암 분야에서 리포솜 의약품의 채택 확대와 맞춤형 의료에 대한 관심 증가는 향후 몇 년 동안 시장 역학을 형성할 것으로 예상됩니다. 전반적으로 리포좀 독소루비신 시장은 약물전달 시스템 및 암 치료의 발전과 함께 견조한 성장세를 이어갈 것으로 예상됩니다.

리포좀 독소루비신 시장 보고서 하이라이트

제형별로는 동결건조 분말 제형이 안정성과 보존기간이 길어 시장을 독점하고 있습니다.

제품별로는 높은 브랜드 인지도와 다양한 암 치료 효과로 인해 독실 제제가 시장을 주도하고 있습니다. 리포독스(Lipodox) 부문도 독실 대신 비용 효율적인 대안으로 인기를 끌고 있습니다.

안트라사이클린계 항생제 부문은 암 분야에서의 폭넓은 적용 범위와 확립된 임상적 유용성으로 인해 시장을 선도하고 있습니다.

투여 경로별로는 비경구 투여가 주류를 이루고 있으며, 이는 암 치료에서 직접적이고 효과적인 투여 방법을 반영하고 있습니다. 그러나 잠재적인 편의성과 효과로 인해 다른 투여 경로가 검토되고 있습니다.

용도별로는 유방암 분야가 높은 발병률과 치료법의 발전으로 인해 가장 큰 점유율을 차지하고 있습니다. 방광암, 림프종 등 다른 분야도 성장하고 있지만 그 속도는 느립니다.

리포좀 독소루비신의 주요 최종사용자는 병원이며, 고급 치료 프로토콜과 환자 관리 능력이 그 원동력이 되고 있습니다. 전문 센터는 특정 암 치료에 중점을 두기 때문에 채택이 증가하고 있습니다.

북미는 높은 수준의 의료 인프라와 혁신적인 치료법 채택률로 인해 지배적인 지역으로 부상했습니다. 아시아태평양은 의료 투자 증가와 암 발병률 증가에 힘입어 가장 높은 성장률을 보이는 시장입니다.

이 시장의 주요 기업으로는 Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical. 등이 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 조사 방법

제4장 세계의 리포좀 독소루비신 시장 인사이트

  • 시장 현황
  • 리포좀 독소루비신 시장 역학
    • 성장 촉진요인과 기회
      • 표적 암 치료 채용 증가
      • 종양학 조사에 대한 투자 증가
    • 성장 억제요인과 과제
      • 리포좀 독소루비신은 멍과 출혈을 유발할 수 있다
  • PESTEL 분석
  • 리포좀 독소루비신 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 리포좀 독소루비신 시장 : 제제별

  • 주요 조사 결과
  • 소개
  • 동결건조 분말
  • 독소루비신 주사

제6장 세계의 리포좀 독소루비신 시장 : 제품별

  • 주요 조사 결과
  • 소개
  • 독실
  • 리포독스
  • 마이오셋
  • 기타

제7장 세계의 리포좀 독소루비신 시장 : 유형별

  • 주요 조사 결과
  • 소개
  • 안트라사이클린계 항생제
  • 기타

제8장 세계의 리포좀 독소루비신 시장 : 투여 경로별

  • 주요 조사 결과
  • 소개
  • 비경구
  • 기타

제9장 세계의 리포좀 독소루비신 시장 : 용도별

  • 주요 조사 결과
  • 소개
  • 방광암
  • 카포시육종
  • 백혈병
  • 림프종
  • 유방암
  • 기타

제10장 세계의 리포좀 독소루비신 시장 : 최종사용자별

  • 주요 조사 결과
  • 소개
  • 병원
  • 홈케어
  • 전문 센터
  • 기타

제11장 세계의 리포좀 독소루비신 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 리포좀 독소루비신 시장 평가 : 지역별, 2020-2034년
  • 북미
    • 북미 : 제제별, 2020-2034년
    • 북미 : 제품별, 2020-2034년
    • 북미 : 유형별, 2020-2034년
    • 북미 : 투여 경로별, 2020-2034년
    • 북미 : 용도별, 2020-2034년
    • 북미 : 최종사용자별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 제제별, 2020-2034년
    • 유럽 : 제품별, 2020-2034년
    • 유럽 : 유형별, 2020-2034년
    • 유럽 : 투여 경로별, 2020-2034년
    • 유럽 : 용도별, 2020-2034년
    • 유럽 : 최종사용자별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 제제별, 2020-2034년
    • 아시아태평양 : 제품별, 2020-2034년
    • 아시아태평양 : 유형별, 2020-2034년
    • 아시아태평양 : 투여 경로별, 2020-2034년
    • 아시아태평양 : 용도별, 2020-2034년
    • 아시아태평양 : 최종사용자별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 제제별, 2020-2034년
    • 중동 및 아프리카 : 제품별, 2020-2034년
    • 중동 및 아프리카 : 유형별, 2020-2034년
    • 중동 및 아프리카 : 투여 경로별, 2020-2034년
    • 중동 및 아프리카 : 용도별, 2020-2034년
    • 중동 및 아프리카 : 최종사용자별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 제제별, 2020-2034년
    • 라틴아메리카 : 제품별, 2020-2034년
    • 라틴아메리카 : 유형별, 2020-2034년
    • 라틴아메리카 : 투여 경로별, 2020-2034년
    • 라틴아메리카 : 용도별, 2020-2034년
    • 라틴아메리카 : 최종사용자별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제12장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제13장 기업 개요

  • Johnson & Johnson
  • Lipoxen
  • Pfizer
  • Mylan
  • Teva Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Hengrui Medicine
  • Inovio Pharmaceuticals
  • Aurobindo Pharma
  • Emcure Pharmaceuticals
  • Theradex Pharmaceuticals
  • Astellas Pharma
ksm 25.01.31

The global liposomal doxorubicin market size is expected to reach USD 2.38 billion by 2034, according to a new study by Polaris Market Research. The report "Liposomal Doxorubicin Market Size, Share, Trends, Industry Analysis Report: By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Product (Doxil, Lipodox, Myocet, and Others), Type (Anthracycline Antibiotic and Others), Route of Administration (Parenteral and Others), Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), End User (Hospitals, Homecare, Specialty Centers, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The liposomal doxorubicin market is experiencing significant growth due to increasing cancer prevalence and the rising demand for effective targeted therapies. The drug's ability to reduce side effects compared to conventional doxorubicin and its improved delivery mechanism that enhances therapeutic efficacy also drive the market growth.

Ongoing research and development, which focuses on expanding indications and improving formulation technologies, is expected to offer lucrative opportunities for the market during the forecast period. Future trends, such as the growing adoption of liposomal drugs in oncology and the emphasis on personalized medicines, are expected to shape the market dynamics in the coming years. Overall, the liposomal doxorubicin market is poised for robust growth as advancements in drug delivery systems and cancer treatment continue to evolve.

Liposomal Doxorubicin Market Report Highlights:

By drug formulation, the lyophilized powder segment dominates the market due to its stability and longer shelf life.

In terms of product, the Doxil segment leads this market, driven by its strong brand recognition and effectiveness in treating various cancers. The Lipodox segment is also gaining traction as a cost-effective alternative to Doxil.

The anthracycline antibiotic segment, by type, leads the market due to its broad application in oncology and established clinical benefits.

By route of administration, the parenteral route is the dominant method, reflecting its direct and effective delivery in cancer treatment. However, alternative routes are being explored for their potential convenience and efficacy.

Based on application, the breast cancer segment holds the largest share due to its high incidence rate and ongoing advancements in treatment options. Other segments, such as bladder cancer and lymphoma, are also growing but at a slower pace.

Hospitals are the primary end users of liposomal doxorubicin, driven by their capacity for advanced treatment protocols and patient management. Specialty Centers are showing increasing adoption due to their focus on specific cancer treatments.

North America is the dominant region due to advanced healthcare infrastructure and high adoption rates of innovative therapies. Asia Pacific is the highest-growing market, propelled by increasing healthcare investments and rising cancer prevalence.

Some of the key companies in the market are Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical.

Polaris Market Research has segmented the liposomal doxorubicin market report on the basis of drug formulation, product, type, route of administration, application, end user, and region:

By Drug Formulation Outlook (Revenue - USD Billion, 2020-2034)

  • Lyophilized Powder
  • Doxorubicin Injection

By Product Outlook (Revenue - USD Billion, 2020-2034)

  • Doxil
  • Lipodox
  • Myocet
  • Others

By Type Outlook (Revenue - USD Billion, 2020-2034)

  • Anthracycline Antibiotic
  • Others

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

  • Parenteral
  • Others

By Application Outlook (Revenue - USD Billion, 2020-2034)

  • Bladder Cancer
  • Kaposi Sarcoma
  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Liposomal Doxorubicin Market Insights

  • 4.1. Liposomal Doxorubicin Market - Market Snapshot
  • 4.2. Liposomal Doxorubicin Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Adoption of Targeted Cancer Therapies
      • 4.2.1.2. Rising Investments in Oncology Research
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Liposomal doxorubicin may cause bruising and bleeding
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Liposomal Doxorubicin Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Liposomal Doxorubicin Market, by Drug Formulation

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 5.3. Lyophilized Powder
    • 5.3.1. Global Liposomal Doxorubicin Market, by Lyophilized Powder, by Region, 2020-2034 (USD Billion)
  • 5.4. Doxorubicin Injection
      • 5.4.1.1. Global Liposomal Doxorubicin Market, by Doxorubicin Injection, by Region, 2020-2034 (USD Billion)

6. Global Liposomal Doxorubicin Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 6.3. Doxil
    • 6.3.1. Global Liposomal Doxorubicin Market, by Doxil, by Region, 2020-2034 (USD Billion)
  • 6.4. Lipodox
    • 6.4.1. Global Liposomal Doxorubicin Market, by Lipodox, by Region, 2020-2034 (USD Billion)
  • 6.5. Myocet
    • 6.5.1. Global Liposomal Doxorubicin Market, by Myocet, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Liposomal Doxorubicin Market, by Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 7.3. Anthracycline Antibiotic
    • 7.3.1. Global Liposomal Doxorubicin Market, by Anthracycline Antibiotic, by Region, 2020-2034 (USD Billion)
  • 7.4. Others
    • 7.4.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Liposomal Doxorubicin Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.3. Parenteral
    • 8.3.1. Global Liposomal Doxorubicin Market, by Parenteral, by Region, 2020-2034 (USD Billion)
  • 8.4. Others
    • 8.4.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Liposomal Doxorubicin Market, by Application

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 9.3. Bladder Cancer
    • 9.3.1. Global Liposomal Doxorubicin Market, by Bladder Cancer, by Region, 2020-2034 (USD Billion)
  • 9.4. Kaposi Sarcoma
    • 9.4.1. Global Liposomal Doxorubicin Market, Kaposi Sarcoma, by Region, 2020-2034 (USD Billion)
  • 9.5. Leukemia
    • 9.5.1. Global Liposomal Doxorubicin Market, by Leukemia, by Region, 2020-2034 (USD Billion)
  • 9.6. Lymphoma
    • 9.6.1. Global Liposomal Doxorubicin Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
  • 9.7. Breast Cancer
    • 9.7.1. Global Liposomal Doxorubicin Market, by Breast Cancer, by Region, 2020-2034 (USD Billion)
  • 9.8. Others
    • 9.8.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

10. Global Liposomal Doxorubicin Market, by End User

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 10.3. Hospitals
    • 10.3.1. Global Liposomal Doxorubicin Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 10.4. Homecare
    • 10.4.1. Global Liposomal Doxorubicin Market, by Homecare, by Region, 2020-2034 (USD Billion)
  • 10.5. Specialty Centers
    • 10.5.1. Global Liposomal Doxorubicin Market, Specialty Centers, by Region, 2020-2034 (USD Billion)
  • 10.6. Others
    • 10.6.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

11. Global Liposomal Doxorubicin Market, by Geography

  • 11.1. Key Findings
  • 11.2. Introduction
    • 11.2.1. Liposomal Doxorubicin Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 11.3. Liposomal Doxorubicin Market - North America
    • 11.3.1. North America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.3.2. North America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.3.3. North America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.3.4. North America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.3.5. North America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.3.6. North America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.3.7. Liposomal Doxorubicin Market - U.S.
      • 11.3.7.1. U.S.: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.3.7.2. U.S.: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.3.7.3. U.S.: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.3.7.4. U.S.: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.3.7.5. U.S.: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.3.7.6. U.S.: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.3.8. Liposomal Doxorubicin Market - Canada
      • 11.3.8.1. Canada: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.3.8.2. Canada: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.3.8.3. Canada: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.3.8.4. Canada: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.3.8.5. Canada: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.3.8.6. Canada: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4. Liposomal Doxorubicin Market - Europe
    • 11.4.1. Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.2. Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.3. Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.4. Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.5. Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.6. Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.7. Liposomal Doxorubicin Market - UK
      • 11.4.7.1. UK: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.7.2. UK: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.7.3. UK: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.7.4. UK: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.7.5. UK: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.7.6. UK: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.8. Liposomal Doxorubicin Market - France
      • 11.4.8.1. France: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.8.2. France: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.8.3. France: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.8.4. France: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.8.5. France: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.8.6. France: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.9. Liposomal Doxorubicin Market - Germany
      • 11.4.9.1. Germany: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.9.2. Germany: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.9.3. Germany: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.9.4. Germany: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.9.5. Germany: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.9.6. Germany: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.10. Liposomal Doxorubicin Market - Italy
      • 11.4.10.1. Italy: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.10.2. Italy: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.10.3. Italy: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.10.4. Italy: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.10.5. Italy: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.10.6. Italy: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.11. Liposomal Doxorubicin Market - Spain
      • 11.4.11.1. Spain: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.11.2. Spain: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.11.3. Spain: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.11.4. Spain: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.11.5. Spain: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.11.6. Spain: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.12. Liposomal Doxorubicin Market - Netherlands
      • 11.4.12.1. Netherlands: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.12.2. Netherlands: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.12.3. Netherlands: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.12.4. Netherlands: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.12.5. Netherlands: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.12.6. Netherlands: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.13. Liposomal Doxorubicin Market - Russia
      • 11.4.13.1. Russia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.13.2. Russia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.13.3. Russia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.13.4. Russia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.13.5. Russia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.13.6. Russia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.4.14. Liposomal Doxorubicin Market - Rest of Europe
      • 11.4.14.1. Rest of Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.4.14.2. Rest of Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.4.14.3. Rest of Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.4.14.4. Rest of Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.4.14.5. Rest of Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.4.14.6. Rest of Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5. Liposomal Doxorubicin Market - Asia Pacific
    • 11.5.1. Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.2. Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.3. Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.4. Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.5. Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.6. Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.7. Liposomal Doxorubicin Market - China
      • 11.5.7.1. China: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.7.2. China: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.7.3. China: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.7.4. China: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.7.5. China: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.7.6. China: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.8. Liposomal Doxorubicin Market - India
      • 11.5.8.1. India: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.8.2. India: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.8.3. India: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.8.4. India: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.8.5. India: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.8.6. India: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.9. Liposomal Doxorubicin Market - Malaysia
      • 11.5.9.1. Malaysia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.9.2. Malaysia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.9.3. Malaysia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.9.4. Malaysia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.9.5. Malaysia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.9.6. Malaysia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.10. Liposomal Doxorubicin Market - Japan
      • 11.5.10.1. Japan: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.10.2. Japan: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.10.3. Japan: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.10.4. Japan: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.10.5. Japan: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.10.6. Japan: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.11. Liposomal Doxorubicin Market - Indonesia
      • 11.5.11.1. Indonesia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.11.2. Indonesia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.11.3. Indonesia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.11.4. Indonesia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.11.5. Indonesia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.11.6. Indonesia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.12. Liposomal Doxorubicin Market - South Korea
      • 11.5.12.1. South Korea: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.12.2. South Korea: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.12.3. South Korea: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.12.4. South Korea: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.12.5. South Korea: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.12.6. South Korea: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.13. Liposomal Doxorubicin Market - Australia
      • 11.5.13.1. Australia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.13.2. Australia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.13.3. Australia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.13.4. Australia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.13.5. Australia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.13.6. Australia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.5.14. Liposomal Doxorubicin Market - Rest of Asia Pacific
      • 11.5.14.1. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.5.14.2. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.5.14.3. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.5.14.4. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.5.14.5. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.5.14.6. Rest of Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6. Liposomal Doxorubicin Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.2. Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.3. Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.4. Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.5. Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.6. Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.6.7. Liposomal Doxorubicin Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.6.7.2. Saudi Arabia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.6.8. Liposomal Doxorubicin Market - UAE
      • 11.6.8.1. UAE: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.6.8.2. UAE: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.6.8.3. UAE: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.6.8.4. UAE: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.6.8.5. UAE: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.6.8.6. UAE: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.6.9. Liposomal Doxorubicin Market - Israel
      • 11.6.9.1. Israel: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.6.9.2. Israel: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.6.9.3. Israel: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.6.9.4. Israel: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.6.9.5. Israel: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.6.9.6. Israel: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.6.10. Liposomal Doxorubicin Market - South Africa
      • 11.6.10.1. South Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.6.10.2. South Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.6.10.3. South Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.6.10.4. South Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.6.10.5. South Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.6.10.6. South Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.6.11. Liposomal Doxorubicin Market - Rest of Middle East & Africa
      • 11.6.11.1. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.6.11.2. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.6.11.3. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.6.11.4. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.6.11.5. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.6.11.6. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.7. Liposomal Doxorubicin Market - Latin America
    • 11.7.1. Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.7.2. Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.7.3. Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.7.4. Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.7.5. Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.7.6. Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.7.7. Liposomal Doxorubicin Market - Mexico
      • 11.7.7.1. Mexico: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.7.7.2. Mexico: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.7.7.3. Mexico: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.7.7.4. Mexico: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.7.7.5. Mexico: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.7.7.6. Mexico: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.7.8. Liposomal Doxorubicin Market - Brazil
      • 11.7.8.1. Brazil: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.7.8.2. Brazil: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.7.8.3. Brazil: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.7.8.4. Brazil: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.7.8.5. Brazil: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.7.8.6. Brazil: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.7.9. Liposomal Doxorubicin Market - Argentina
      • 11.7.9.1. Argentina: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.7.9.2. Argentina: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.7.9.3. Argentina: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.7.9.4. Argentina: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.7.9.5. Argentina: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.7.9.6. Argentina: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
    • 11.7.10. Liposomal Doxorubicin Market - Rest of Latin America
      • 11.7.10.1. Rest of Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
      • 11.7.10.2. Rest of Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
      • 11.7.10.3. Rest of Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
      • 11.7.10.4. Rest of Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
      • 11.7.10.5. Rest of Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
      • 11.7.10.6. Rest of Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Johnson & Johnson
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. Lipoxen
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. Pfizer
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. Mylan
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Teva Pharmaceuticals
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Sun Pharmaceutical Industries
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. Hengrui Medicine
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. Inovio Pharmaceuticals
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. Aurobindo Pharma
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. Emcure Pharmaceuticals
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. Theradex Pharmaceuticals
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Astellas Pharma
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제